Lista de obras -

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

artículo científico publicado en 2019

A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

artículo científico publicado en 2016

A snapshot of COVID-19 infection in patients with solid tumors

scientific article published on 03 December 2020

Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study

scientific article published on 27 October 2020

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

scientific article published on 22 January 2020

Chemotherapy-induced response of liver hemangiomas in a patient with a germ cell tumor: a case report.

artículo científico publicado en 2018

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

scientific article published on 20 August 2018

Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

artículo científico publicado en 2012

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

scientific article published on 01 July 2019

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1

artículo científico publicado en 2020

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

scientific article published on 01 January 2019

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

artículo científico publicado en 2020

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

artículo científico publicado en 2018

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

artículo científico publicado en 2018

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

artículo científico publicado en 2019

Management of gynecological cancer in pregnant patients

scientific article published on 11 October 2018

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

scientific article published on 24 December 2018

Novel targeted therapies in ovarian and uterine carcinosarcomas

scientific article published on 01 June 2018

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

scientific article published on 18 August 2019

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

artículo científico publicado en 2019

PI3K-Akt signaling controls PFKFB3 expression during human T-lymphocyte activation.

artículo científico publicado en 2018

Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain ⬇️

artículo científico publicado el 3 de marzo de 2013

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

artículo científico publicado en 2020

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

scientific article published on 04 February 2020

Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study

artículo científico publicado en 2015

Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib

artículo científico publicado en 2015

Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

artículo científico publicado en 2020

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

artículo científico publicado en 2012

Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer

scientific article published on 22 November 2018

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

scientific article published on 17 October 2019

Lista de obras de

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

A snapshot of COVID-19 infection in patients with solid tumors

Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Chemotherapy-induced response of liver hemangiomas in a patient with a germ cell tumor: a case report.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

Management of gynecological cancer in pregnant patients

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Novel targeted therapies in ovarian and uterine carcinosarcomas

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

PI3K-Akt signaling controls PFKFB3 expression during human T-lymphocyte activation.

Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain ⬇️

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study

Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib

Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy